TY - JOUR

T1 - European guidelines on microscopic colitis

T2 - United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations

AU - Miehlke, Stephan

AU - Guagnozzi, Danila

AU - Zabana, Yamile

AU - Tontini, Gian E.

AU - Fiehn, Anne Marie Kanstrup

AU - Wildt, Signe

AU - Bohr, Johan

AU - Bonderup, Ole

AU - Bouma, Gerd

AU - D’Amato, Mauro

AU - Engel, Peter Johan Heiberg

AU - Fernandez-Banares, Fernando

AU - Macaigne, Gilles

AU - Hjortswang, Henrik

AU - Hultgren-Hörnquist, Elisabeth

AU - Koulaouzidis, Anastasios

AU - Kupcinskas, Jouzas

AU - Landolfi, Stefania

AU - Latella, Giovanni

AU - Lucendo, Alfredo

AU - Lyutakov, Ivan

AU - Madisch, Ahmed

AU - Magro, Fernando

AU - Marlicz, Wojciech

AU - Mihaly, Emese

AU - Munck, Lars Kristian

AU - Ostvik, Ann Elisabeth

AU - Patai, Árpád V.

AU - Penchev, Plamen

AU - Skonieczna-Żydecka, Karolina

AU - Verhaegh, Bas

AU - Münch, Andreas

PY - 2021

Y1 - 2021

N2 - Introduction: Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, non-bloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from this disorder. Methods: Guidelines were developed by members from the European Microscopic Colitis Group and United European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon using the Delphi method. Results: These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice. Conclusion: These guidelines may support clinicians worldwide to improve the clinical management of patients with microscopic colitis.

AB - Introduction: Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, non-bloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from this disorder. Methods: Guidelines were developed by members from the European Microscopic Colitis Group and United European Gastroenterology in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument. Following a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the certainty of the evidence. Statements and recommendations were developed by working groups consisting of gastroenterologists, pathologists and basic scientists, and voted upon using the Delphi method. Results: These guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice. Conclusion: These guidelines may support clinicians worldwide to improve the clinical management of patients with microscopic colitis.

KW - budesonide

KW - diarrhoea

KW - inflammatory bowel disease

KW - Microscopic colitis

U2 - 10.1177/2050640620951905

DO - 10.1177/2050640620951905

M3 - Review

C2 - 33619914

AN - SCOPUS:85089703028

VL - 9

SP - 13

EP - 37

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 1

ER -